ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia
Primary Purpose
Obstetric Anesthesia, Spinal Anesthesia, Hypotension
Status
Unknown status
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Hydroxyethylstarch 130/0.4
Sponsored by
About this trial
This is an interventional treatment trial for Obstetric Anesthesia focused on measuring Obstetric anesthesia, Spinal anesthesia, Hypotension, Fluid therapy, Cesarean section, phenylephrine, cardiac output
Eligibility Criteria
Inclusion Criteria:
- Healthy pregnant women (ASA I or II)
- Normal pregnancy
- Term gestation (37 weeks and above)
- Elective cesarean section
- Spinal anesthesia
Exclusion Criteria:
- Cardiopathies
- Hypertensive disease/ pre-eclampsia / eclampsia
- Any contraindication to neuraxial anesthesia
- Patient refusal
- Body mass index > 30 at first antenatal visit and > 32 at cesarean section
- Twin pregnancy
- Known allergies to HES
- Emergency cesarean section
Sites / Locations
- Maisonneuve-Rosemont HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Hydroxyethylstarch 130/0.4
Arm Description
Outcomes
Primary Outcome Measures
Volume of HES which will prevent hypotension if 50 % of the subjects.
Secondary Outcome Measures
Incidence of hypotension episodes
Incidence of hypertensive episodes
cardiac output
Apgar score
umbilical artery pH
additional vasopressors administered
Full Information
NCT ID
NCT01415284
First Posted
August 10, 2011
Last Updated
February 12, 2013
Sponsor
Maisonneuve-Rosemont Hospital
Collaborators
Université de Montréal
1. Study Identification
Unique Protocol Identification Number
NCT01415284
Brief Title
ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia
Official Title
ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Unknown status
Study Start Date
October 2011 (undefined)
Primary Completion Date
June 2013 (Anticipated)
Study Completion Date
June 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maisonneuve-Rosemont Hospital
Collaborators
Université de Montréal
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this trial is to determine the effective volume of hydroxyethylstarch 130/0.4 which would prevent the occurence of maternal hypotension in 50% of healthy pregnant women undergoing a cesarean section under spinal anesthesia.
Detailed Description
The incidence of spinal anesthesia-induced hypotension in pregnant women undergoing a cesarean section is high. A preoperative fluid bolus of undetermined volume is frequently administered to lower the incidence of maternal hypotension, with a somewhat poor efficacy. Recently, several investigations have shown that the use of a phenylephrine infusion after the induction of spinal anesthesia results in a significant reduction in hypotensive episodes. Given the high efficacy of this therapy (incidence of hypotension around 20%), it is possible to determine the effective volume of fluid which would prevent hypotension in 50% of the patients studied (ED50).
Healthy term pregnant women undergoing elective cesarean section under spinal anesthesia will be recruited in this trial. The spinal anesthesia regimen will be standardized and all subjects will receive a phenylephrine infusion. The fluid investigated is hydroxyethylstarch (HES) 130/0.4 (Volulyte(R)). The ED50 will be determined using an up-down sequential allocation method initially described by Dixon & Massey. The determination of the HES ED50 will help the anesthesiologist in further treating maternal hypotension appropriately.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstetric Anesthesia, Spinal Anesthesia, Hypotension, Fluid Therapy, Cesarean Section
Keywords
Obstetric anesthesia, Spinal anesthesia, Hypotension, Fluid therapy, Cesarean section, phenylephrine, cardiac output
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Hydroxyethylstarch 130/0.4
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Hydroxyethylstarch 130/0.4
Other Intervention Name(s)
Voluven
Intervention Description
first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
Primary Outcome Measure Information:
Title
Volume of HES which will prevent hypotension if 50 % of the subjects.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Incidence of hypotension episodes
Time Frame
1 hour
Title
Incidence of hypertensive episodes
Time Frame
1 hour
Title
cardiac output
Time Frame
1 hour
Title
Apgar score
Time Frame
10 minutes
Title
umbilical artery pH
Time Frame
2 hours
Title
additional vasopressors administered
Time Frame
1 hour
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy pregnant women (ASA I or II)
Normal pregnancy
Term gestation (37 weeks and above)
Elective cesarean section
Spinal anesthesia
Exclusion Criteria:
Cardiopathies
Hypertensive disease/ pre-eclampsia / eclampsia
Any contraindication to neuraxial anesthesia
Patient refusal
Body mass index > 30 at first antenatal visit and > 32 at cesarean section
Twin pregnancy
Known allergies to HES
Emergency cesarean section
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Loubert, MD, FRCPC
Phone
514.252.3426
Email
loubertch@yahoo.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Louis-Philippe Fortier, MD, FRCPC
Phone
514.252.3426
Email
lpfortier@mac.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian Loubert, MD, FRCPC
Organizational Affiliation
Maisonneuve-Rosemont Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maisonneuve-Rosemont Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Loubert, MD, FRCPC
Phone
514.252.3426
Email
loubertch@yahoo.fr
First Name & Middle Initial & Last Name & Degree
Louis-Philippe Fortier, MD, FRCPC
Phone
514.252.3426
Email
lpfortier@mac.com
First Name & Middle Initial & Last Name & Degree
Christian Loubert, MD, FRCPC
First Name & Middle Initial & Last Name & Degree
Pierre-Olivier Gagnon, MD
First Name & Middle Initial & Last Name & Degree
Louis-Philippe Fortier, MD, FRCPC
First Name & Middle Initial & Last Name & Degree
Pierre Drolet, MD,FRCPC
12. IPD Sharing Statement
Learn more about this trial
ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia
We'll reach out to this number within 24 hrs